19-ID-214: A Phase I, Observer-Blind, Randomized, Placebo-Controlled Study to Assess Safety, Immunogenicity and Efficacy of GSK S. AUREUS Candidate Vaccine when Administered to Healthy Adults (Dose-Escalation) and to Adults 18 TO 50 Years of Age with a R

Grants and Contracts Details

StatusActive
Effective start/end date4/30/20 → 9/26/25

Funding

  • Corixa Corporation: $171,202.00